Contra-indicated in patients who have had anaphylaxis with belimumab.
- TRADE NAME: Benlysta (GSK)
- INDICATIONS: Systemic lupus erythematosus
- CLASS: Immunosuppressant, Monoclonal antibody
- HALF-LIFE: 19.4 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Biologic therapies, Cyclophosphamide, Denileukin, Live vaccines, Typhoid Vaccine, Yellow Fever Vaccine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of belimumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/21/2024
